Yoshio Ijiri
Overview
Explore the profile of Yoshio Ijiri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kato R, Ijiri Y, Hayashi T, Uetrecht J
J Toxicol Sci
. 2020 Nov;
45(11):673-680.
PMID: 33132241
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been approved for non-small cell lung cancer. Although EGFR TKIs are less toxic than traditional cytotoxic therapies, they cause...
12.
Nakagawa T, Furukawa Y, Hayashi T, Nomura A, Yokoe S, Moriwaki K, et al.
Hypertens Res
. 2019 Aug;
42(12):1858-1871.
PMID: 31409917
Type 2 diabetes mellitus (TDM) has been reported to be associated with cardiac remodeling. Although O-GlcNAcylation is known to be elevated in diabetic and ischemic hearts, the effects of O-GlcNAcylation...
13.
Kato R, Ijiri Y, Hayashi T, Uetrecht J
Drug Metab Dispos
. 2019 Jul;
47(10):1093-1096.
PMID: 31324698
Although the pathophysiology of carbamazepine-induced idiosyncratic or hypersensitivity reactions is unclear, they are presumed to be immune mediated, involving a complex interaction between drug metabolism and activation of the immune...
14.
Kato R, Sato T, Iwamoto A, Yamazaki T, Nakashiro S, Yoshikai S, et al.
Biopharm Drug Dispos
. 2019 Jun;
40(7):242-249.
PMID: 31219617
The protein binding rates (PBR) of platinum-containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) have been reported as 98%, 25-50% and 98%, respectively. To investigate the protein-binding properties of...
15.
Imano H, Kato R, Tanikawa S, Yoshimura F, Nomura A, Ijiri Y, et al.
J Pharmacol Sci
. 2018 Jul;
137(3):274-282.
PMID: 30055890
Patients with obstructive sleep apnea (OSA) have a high prevalence of atrial fibrillation (AF). Rivaroxaban, a coagulation factor Xa inhibitor, has recently been reported to show pleiotropic effects. This study...
16.
Hannya N, Ogita-Nakanishi H, Kato R, Ijiri Y, Hayashi T, Tanaka K, et al.
Microbiol Immunol
. 2017 Dec;
62(2):99-110.
PMID: 29193290
There was a significant amount of non-specific, but not of allergen (e.g., papain, mite feces and four kinds of pollen)-specific, IgE antibodies (Abs) in the sera of normal mice. An...
17.
Ijiri Y, Kato R, Sasaki D, Amano F, Tanaka K, Hayashi T
Toxicol Rep
. 2017 Oct;
1:1062-1067.
PMID: 28962318
The circulating soluble tumor necrosis factor (sTNF) and sTNF-receptor (R) 1 and -R2 have known as septic biomarker. The pungent component of capsicum, capsaicin (Cap), has several associated physiological activities,...
18.
Woo E, Kato R, Imano H, Fujiwara Y, Ijiri Y, Okada Y, et al.
Curr Vasc Pharmacol
. 2017 May;
15(6):589-598.
PMID: 28460626
Background: Sugen5416 (semaxinib) is an inhibitor of the vascular endothelial growth factor (VEGF) receptor. A rat model of Pulmonary Arterial Hypertension (PAH), created with Sugen5416 and chronic hypoxia, is known...
19.
Ijiri Y, Kato R, Sadamatsu M, Takano M, Yasuda Y, Tanaka F, et al.
Xenobiotica
. 2017 Jan;
48(1):60-72.
PMID: 28081667
1. Drug-induced liver injury is difficult to predict at the pre-clinical stage. This study aimed to clarify the roles of caspase-8 and -9 in CYP2E1 metabolite-induced liver injury in both...
20.
Kato R, Sato T, Kanamori M, Miyake M, Fujimoto A, Ogawa K, et al.
Biol Pharm Bull
. 2016 Dec;
40(3):290-296.
PMID: 27980242
Cisplatin is the most widely used anticancer drug in the world. Mono-chloro and none-chloro complexes of cisplatin may be believed to be the activated compounds. The separation of these compounds...